Abstract: Objective To investigate such adverse reactions as multi-organ immune injury induced by serplulimab, and to provide a reference for safe clinical practice. Methods One case of multi-organ immune injury induced by serplulimab in an elderly patient with colon tumors was analyzed, and a summary was made after literature review. Results Based on the patient's clinical manifestations, results of laboratory tests, and the temporal association with drug administration,the patient's multi-organ immune injury was considered to have been caused by serplulimab. The patient improved and was discharged after glucocorticoid therapy. However, the adverse reactions progressed because the patient failed to take the prescribed drugs or monitor for adverse reactions after discharge. Conclusion The incidence of ICIs-associated multi-organ immune injury is relatively low, but the fatality is exceedingly high. Clinicians should assess the risk before administering serplulimab, closely monitor patients during treatment, and remain alert to the risk of serplulimab-induced multi-organ immune injury.

Key words: Serplulimab, Myocarditis, Myasthenia gravis, Myositis, PD-1, ICIs